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Abstract
 
Thrombospondin 1 (TSP) elicits potent antiinflammatory activities in vivo, as evidenced by
persistent, multiorgan inflammation in TSP null mice. Herein, we report that DCs represent an
abundant source of TSP at steady state and during activation. Human monocyte-derived
immature dendritic cells (iDCs) spontaneously produce TSP, which is strongly enhanced by
PGE
 
2
 
 and to a lesser extent by transforming growth factor (TGF) 
 
 
 
, two soluble mediators
secreted by macrophages after engulfment of damaged tissues. Shortly after activation via
danger signals, DCs transiently produce interleukin (IL) 12 and tumor necrosis factor (TNF) 
 
 
 
,
thereby eliciting protective and inflammatory immune responses. Microbial stimuli increase
TSP production, which is further enhanced by IL-10 or TGF-
 
 
 
. The endogenous TSP pro-
duced during early DC activation negatively regulates IL-12, TNF-
 
 
 
, and IL-10 release
through its interactions with CD47 and CD36. After prolonged activation, DCs extinguish
their cytokine synthesis and become refractory to subsequent stimulation, thereby favoring the
return to steady state. Such “exhausted” DCs continue to release TSP but not IL-10. Disrupting
TSP–CD47 interactions during their restimulation restores their cytokine production. We
conclude that DC-derived TSP serves as a previously unappreciated negative regulator contrib-
uting to arrest of cytokine production, further supporting its fundamental role in vivo in the
active resolution of inflammation and maintenance of steady state.
Key words: PGE
 
2
 
 • TGF-
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Introduction
 
DCs play a central role in the induction of immunity and
tolerance (1). In the absence of inflammation, immature
DCs (iDCs) located in peripheral tissues are specialized in
uptake of innocuous and cell-associated self Ag. They con-
tinuously capture Ag and migrate to the draining lymph
node, where they can induce tolerance (1). Under the in-
fluence of danger signals (i.e., pathogens and necrotic cells),
DCs undergo a process called maturation manifest by up-
regulation of costimulatory molecules, secretion of pro- and
antiinflammatory cytokines, and the ability to stimulate the
differentiation of naive T cells into effector cells. Cytokine
production by activated DCs (IL-12, TNF-
 
 
 
, and IL-10) is
transient; after prolonged stimulation, DCs become refrac-
tory to subsequent activation signals (2). Although delayed
production of IL-10 partially contributes to the arrest of
cytokine production by activated DCs and the return to
steady state, the immune system relies on additional negative
feedback mechanisms to down-regulate proinflammatory
cytokine release and/or terminate the response to Ag. These
include soluble mediators such as PGE
 
2
 
, cyclopentenone
PGs, and lipoxin A4 (3–5), or ligation of certain cell surface
receptors (i.e., CD36, CD47, and CD51/CD61; references
6, 7). The latter receptors bind thrombospondin 1 (TSP), an
extracellular matrix (ECM) protein predominantly secreted by
platelets, monocytes, macrophages, and several nonhemato-
poietic cell types (8, 9). Also, TSP binds additional receptors
as follows: 
 
 
 
3
 
 
 
1, 
 
 
 
IIb
 
 
 
3, and cellular glycosaminoglycans.
As a consequence of its binding to several cell surface re-
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ceptors, TSP exerts myriad effects on cell function, which
sometimes appear to be contradictory (10, 11). Some studies
have shown that TSP promotes cell migration, cell adhe-
sion, and T cell activation (for reviews see references 10 and
12). It inhibits angiogenesis, cell migration, and T cell acti-
vation, and promotes apoptosis (for reviews see references
10 and 12). Notably, TSP is composed of several distinct
structural domains that specifically interact with a range of
cellular receptors differentially expressed by a variety of cells
(12), which could explain its broad spectrum of biological
activities. Nevertheless, TSP displays predominantly antiin-
flammatory activities in vivo as strongly suggested by the in-
flammatory phenotype of TSP null mice (13).
We reported previously that CD47 ligation by anti-CD47
monoclonal antibodies or by TSP selectively down-regulates
IL-12 production by monocytes. Moreover, CD47 ligation
inhibits DC phenotypic maturation and cytokine release
while leaving TGF
 
 
 
 secretion intact (7, 14). Although TSP
is a major activator of TGF-
 
 
 
, which itself prevents DC
maturation, the TSP inhibitory effect on APCs was shown
to be independent of both TGF-
 
 
 
 and IL-10 (7, 13, 15).
Here, we demonstrate that iDCs express and secrete TSP,
and show that TSP production is regulated by soluble medi-
ators and maturation signals. Our results also support the
negative regulatory effects of DC-derived TSP on cytokine
release (i.e., IL-12, TNF-
 
 
 
, and IL-10) through interactions
with CD36 and CD47 during early DC activation. Interest-
ingly, only TSP–CD47 interactions appear to contribute to
refractoriness of fully mature DCs to additional activation
signals, suggesting an active role for TSP in the resolution of
the inflammatory response after an environmental insult.
 
Materials and Methods
 
Dendritic Cell Preparation and Culture Conditions.
 
Peripheral
blood mononuclear cells were isolated by density gradient cen-
trifugation of heparinized blood from healthy volunteers with
Lymphoprep (Nycomed). Monocytes were enriched by cold ag-
gregation, followed by T and NK depletion as reported previ-
ously (14). Monocyte purity was shown to be 
 
 
 
95% CD14
 
 
 
 cells
by flow cytometry. Human monocyte-derived iDCs were pre-
pared exactly as described previously (16). Every other day, two
thirds of culture medium was replaced by fresh medium (RPMI
1640 10% FCS supplemented with 2 mM glutamine, 1 mM so-
dium pyruvate, 10 mM hepes, 100 IU penicillin, and 100 
 
 
 
g/ml
streptomycin, containing GM-CSF and IL-4); nonadherent cells
were harvested at day 5 to obtain iDCs. Mature DCs (mDCs)
were generated after stimulation of iDCs (0.5 
 
 
 
 10
 
6
 
/ml) in com-
plete HB101 medium (Irvine Scientific) or complete medium
(RPMI 1640 10% FCS containing low TSP levels [
 
 
 
30 ng/ml])
for the indicated periods of time. DCs were activated by 
 
Staphylo-
coccus aureus Cowan
 
 I strain (SAC; 0.0025%) (wt/vol; Pansorbin;
Calbiochem), 1 
 
 
 
g/ml LPS or CD40-L L-transfectants (or 1 
 
 
 
g/
ml sCD40-L and 500 U/ml IFN-
 
 
 
). IL-10 and TGF-
 
 
 
 were
used at 10 ng/ml and purchased from R&D Systems, and PGE
 
2
 
was used at 100 nM (Sigma-Aldrich). Neutralizing anti-TSP
mAbs III (clone 6.7) and I (clone A4.1) obtained from Lab Vision
and control mAbs (IgG1 and IgM; Sigma-Aldrich) were used at
10 
 
 
 
g/ml. To examine DC exhaustion, mDCs were washed,
counted, and restimulated overnight with L-transfectants CD40-L
or sCD40-L and IFN-
 
 
 
 in RPMI 1640 10% FCS.
 
GeneChip Expression Analysis.
 
Human genome-wide gene
expression was examined with the Human Genome U133A
probe array (GeneChip; Affymetrix, Inc.), which contains the
oligonucleotide probe set for 
 
 
 
22,000 full-length genes, accord-
ing to the manufacturer’s protocol. Total RNA was extracted
from 
 
 
 
5 
 
 
 
 10
 
6
 
 cells. Double-stranded cDNA was synthesized by
means of Superscript Choice system (Life Technologies) and a
T7-(dt)24 primer (Amersham Biosciences). The cDNA was sub-
jected to the in vitro transcription in the presence of biotinylated
nucleoside [Q]triophosphate by means of a BioArray High Yield
RNA Transcript labeling kit (Enzo Diagnostics). The biotin-
ylated cRNA was hybridized with a probe. After washing, the
hybridized biotinylated cRNA was stained with PE-streptavidin
(Molecular Probes) and scanned with an HP Gene Array Scanner
(Affymetrix, Inc.). The fluorescence intensity of each probe was
quantified with a computer program (Suite 4.0; Affymetrix, Inc.).
Figure 1. Immature and mature DCs express TSP. 0.5   106/ml
monocyte-derived iDCs were cultured for 48 h (A) or the indicated
time (B) in the absence or presence of 1  g/ml LPS or 0.0025%
SAC. Cells were permeabilized, fixed, and stained for intracellular
TSP as described in Materials and Methods. (A) TSP staining is
depicted as follows: iDCs (left, thick line); iDCs (middle, thin
line) versus iDCs   LPS (thick line); and iDCs (right, thin line)
versus iDCs   SAC (thick line). (dotted lines) Isotype control
mAb. Data are from one representative experiment out of three
(A) and out of five (B).T
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Flow Cytometric Analysis.
 
The phenotypes of iDCs and mDCs
were determined by direct staining with PE-CD86 (clone BU63)
and FITC-CD83 (clone HB15e; Becton Dickinson). A three-
step procedure was used for intracytoplasmic detection of TSP. In
brief, brefeldin A was added for the last 5 h of the culture; DCs
were permeabilized with 0.5% saponin and fixed for 5 min with
0.1% paraformaldehyde. Cells were incubated with 2 
 
 
 
g/ml anti-
TSP mAb (clone 6.7 or A3; Lab Vision) for 30 min at 4
 
 
 
C, fol-
lowed by biotinylated goat anti–mouse IgG 
 
  
 
IgM (1/500; Bio-
source International) for 30 min and stained with streptavidin-PE
(Becton Dickinson). Stained cells were analyzed with a FACScal-
ibur™ (Becton Dickinson).
 
Cytokine Measurement.
 
IL-12p70, TNF-
 
 
 
, and IL-10 release
were assessed by two-site sandwich ELISA as described previously
(7). The sensitivity of the assays was 6 pg/ml for IL-12 and 50 pg/
ml for the other cytokines. For TSP measurement, plates were
coated overnight with 0.5 
 
 
 
g/ml anti-TSP mAb (clone P10;
Chemicon) and blocked with PBS containing 2% BSA and 0.1%
Tween 20 for 2 h. After washing, 100-
 
 
 
l samples diluted in
HB101 medium were added overnight. TSP purified from plate-
lets (Calbiochem) was used as a standard. Plates were washed and
incubated with detection polyclonal rabbit anti-TSP Ab (Calbio-
chem) and developed by HRPO-labeled mouse anti–rabbit IgG
and substrate. The sensitivity of the assay was 10 ng/ml.
 
Results
 
Immature and Mature DCs Synthesize TSP.
 
TSP pro-
duced by macrophages facilitates the phagocytosis of apop-
totic cells by establishing a molecular bridge between the
phagocyte and the dying cell (17, 18). The iDC is another
Ag-presenting cell specialized in the uptake of apoptotic
cells, and is the only cell type capable of cell-associated Ag
cross-presentation to naive T cells. Therefore, we postu-
lated that iDCs could represent an additional source of
TSP. Our initial microarray analysis performed on iDCs
isolated from five donors revealed the constitutive presence
of TSP transcript and its up-regulation by SAC (
 
 
 
11-fold)
and LPS (
 
 
 
8-fold) stimulation. By using two complemen-
tary experimental approaches (intracellular staining and
ELISA), we demonstrated that TSP is secreted spontane-
ously by iDCs and that its production is significantly in-
creased during DC maturation. First, we confirmed that
DCs express TSP by intracellular staining (Fig. 1). Indeed,
the staining reveals that TSP is readily detected in the
whole population of unstimulated iDCs. Engagement of
toll-like receptors (TLR) 4 or 2, by LPS and SAC respec-
tively, significantly increases TSP expression (Fig. 1 A)
with maximum levels observed after 48 h of stimulation
(Fig. 1 B, P 
 
  
 
0.05, 
 
n
 
 
 
  
 
5). TSP is hardly detectable in
nonpermeabilized cell preparations, indicating that the vast
majority of TSP is located intracellularly and not on the cell
surface (unpublished data). Second, the measurement of
TSP in the culture supernatant of unstimulated and matur-
ing DCs confirmed that TSP is indeed secreted by DCs
(Fig. 2). TSP production is strongly increased during DC
maturation in response to T cell–dependent or TLR-medi-
ated activation signals (Fig. 2 A, P 
 
  
 
0.05, 
 
n
 
 
 
  
 
9). The lev-
els of spontaneous TSP production plateau between 48 h
and 72 h (Fig. 2 B). Kinetic studies indicate that TSP pro-
duction by maturing DCs is delayed when compared with
that of IL-12 and TNF-
 
 
 
, but simultaneous with that of
IL-10 (Fig. 2, B and C). These data establish that DCs are
an abundant source of TSP in the steady state and that pro-
duction can be enhanced by inflammatory signals.
 
Soluble Mediators Regulate TSP Production by Immature and
Activated DCs.
 
TSP potentiates the phagocytosis of apop-
totic cells by macrophages, leading to the up-regulation of
TGF-
 
 
 
 and PGE
 
2
 
 production by these cells (17, 18).
Therefore, we examined whether PGE
 
2
 
, TGF-
 
 
 
, or IL-10,
each of which exhibits well-established antiinflammatory
properties, would in turn modulate TSP production by im-
mature and maturing DCs. As shown in Fig. 3, TGF-
 
 
 
 but
not IL-10 significantly increases TSP production by iDCs
(Fig. 3 A). In contrast, both cytokines both significantly po-
tentiate TSP production after 24 h of stimulation by SAC
(Fig. 3 B). This enhancing effect is no longer observed after
48 h, when TSP levels reach a plateau (unpublished data).
Figure 2. TSP secretion by activated DCs. (A) Monocyte-derived
iDCs were cultured for 24 h in the absence or presence of LPS, SAC, or
L-CD40L   IFN- . TSP production was determined in the culture super-
natants by ELISA (sensitivity, 10 ng/ml). Data are from one representative
experiment out of three. (B and C) Kinetics of cytokine production by
SAC-activated DCs. Monocyte-derived iDCs were cultured for the indicated
periods of time in the absence or presence of SAC. IL-12, TNF- , IL-10,
and TSP production was determined by ELISA. Data are from one repre-
sentative experiment out of three.T
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Strikingly, PGE
 
2
 
 increases the release of TSP by iDCs by
 
 
 
50-fold (Fig. 3 C) and 1-nM physiological concentrations
of PGE
 
2
 
 are sufficient to increase TSP production (Fig. 3
E); this enhancing effect is confirmed by intracytoplasmic
staining (Fig. 3 F). PGE
 
2
 
 further potentiates TSP secretion
by activated DCs (Fig. 3 C), whereas it significantly down-
regulates IL-12 and TNF-
 
 
 
 release (Fig. 3 D).
We conclude that antiinflammatory molecules, including
PGE
 
2,
 
 IL-10, and TGF-
 
 
 
, provide a positive signal for TSP
secretion by both iDCs and activated DCs. Because exoge-
nous TSP reportedly down-modulates DC maturation (7),
next we examined the role of endogenous TSP in the reg-
ulation of cytokine production.
 
Endogenous TSP Secretion Renders Fully Mature DCs Re-
fractory to Further Activation.
 
TSP can potentially use two
pathways to decrease proinflammatory cytokine release by
maturing DCs. Ligation of CD36 and CD47, two TSP re-
ceptors on DCs, by their respective mAbs reportedly im-
pairs IL-12 secretion (6, 7). Therefore, we attempted to
block TSP binding to CD36 or CD47 at an early stage of
DC activation by adding neutralizing anti-TSP mAbs to-
gether with a TLR activation signal. We found that anti-
TSP mAb III and I, which interfere with the binding of
TSP to CD47 and CD36 respectively, enhance TNF-
 
 
 
,
IL-12, and IL-10 synthesis in response to SAC or in re-
sponse to CD40L plus IFN-
 
 
 
 stimulation (Fig. 4 A and not
depicted). It is worth noting that these mAbs do not by
themselves modulate the expression of costimulatory mole-
cules or affect the ability of DCs to stimulate the prolifera-
tion of allogeneic naive T cells (unpublished data). This in-
dicates that endogenous TSP negatively regulates pro- and
antiinflammatory cytokine release during DC maturation.
Next, we examined the possible role of endogenous TSP
in DC exhaustion. DCs were cultured for 48 h with SAC
(or LPS plus IFN-
 
 
 
), washed, and restimulated for 24 h
with L-CD40L transfectants and IFN-
 
 
 
 (to mimic T cell
interactions) in the presence or absence of the two different
neutralizing anti-TSP mAbs (Fig. 4 B). As reported previ-
ously by Langenkamp et al. (2), DCs have almost extin-
guished their cytokine release after 48-h maturation in re-
sponse to secondary stimulation, resulting in the state
referred to as exhaustion. Interestingly, we found that ex-
hausted DCs still produced large amounts of TSP (ranging
from 1,320 to 3,890 ng/ml; 
 
n
 
 
 
  
 
5). Interruption of TSP–
CD47 interactions (by anti-TSP mAb III) allows DCs to
recover their ability to secrete cytokines. This is not the
case with anti-TSP mAb I (i.e., inhibiting binding of TSP
to CD36) nor with neutralizing anti–IL-10 mAb (unpub-
lished data). The differential effect of the two anti-TSP
mAbs can be partly explained by the loss of CD36 contrast-
Figure 3. IL-10, TGF- , and PGE2 enhance TSP secre-
tion by DCs. (A and B) Monocyte-derived iDCs were
cultured for 24 h in the absence or presence of SAC with
or without IL-10 or TGF- . TSP production was deter-
mined by ELISA and TSP levels expressed in fold increase
compared with iDCs. Mean   SEM of five experiments
(paired Student’s t test; *, P   0.05). (C and D) Monocyte-
derived iDCs were cultured for 24 h in the absence or
presence of SAC with or without 100 nM PGE2. TSP and
IL-12, TNF-  production was determined by ELISA. (C)
TSP levels expressed in fold increase as in A and B. (D) IL-12
and TNF-  levels expressed as percentage of control response
(100%, cytokine production by activated DCs). Mean  
SEM of five experiments (paired Student’s t test; **, P  
0.01). (E) Dose–response curve of PGE2 effect on TSP
secretion by iDCs. (F) Effect of 100 nM PGE2 on intra-
cytoplasmic TSP expression by iDCs. (thin line) TSP
staining of iDCs. (thick line) iDCs   PGE2. (dotted line)
Control mAb. Data are from one representative experiment
out of three for E and F.T
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ing with the stability in CD47 expression during DC matu-
ration (7, 19).
These data suggest that TSP interactions with CD47 and
CD36 inhibit cytokine production at the early stages of DC
activation by TLR ligands, whereas only TSP–CD47 is in-
volved in the negative regulation of cytokine release at the
final stage of DC maturation, when DCs encounter T cells.
In conclusion, we define DC-derived TSP production as a
negative feedback mechanism that is actively involved in
the arrest of cytokine production and the loss of DC re-
sponsiveness to further stimulation.
Discussion
The present findings demonstrate that DCs represent a
previously unknown and abundant source of TSP, both in
the steady state and during activation by danger signals. Ad-
ditionally, we present evidence that endogenous TSP ac-
tively renders DCs refractory to subsequent stimulation
and, thus, contributes to the arrest of the inflammatory re-
sponse. In fact, TSP is rapidly expressed at high levels in in-
flamed and damaged tissues (20). Resolution of inflamma-
tion is now considered to be an active process tightly
regulated by stop signals (21), including antiinflammatory
molecules such as lipid mediators (lipoxins and prostaglan-
din derivatives), TGF- , IL-10, and TSP. Our data are
consistent with the known predominant antiinflammatory
functions of TSP in vitro and in vivo (10). TSP null mice
have persistent inflammation in multiple organs, including
the pancreas and the lung, and display a similar phenotype
as TGF-  null mice (11, 13). TSP is reported to be a major
activator of TGF-  in vivo because a TSP peptide-activat-
ing TGF-  reverses the TSP null phenotype toward wild
type. Here, we show that TGF-  further increases TSP se-
cretion by DCs. These results are in agreement with recent
findings that TGF-  augments TSP expression by macro-
phages, and TGF- –treated APCs promote the generation
of regulatory T cells (22, 23). This positive feedback loop
creates an environment favorable for the induction of ante-
rior chamber-associated immune deviation, a form of toler-
ance ensuring the absence of inflammatory reaction in im-
mune privileged sites.
IL-10 is another major inducer of tolerance and is pres-
ently considered to be the most potent down-regulator of
proinflammatory cytokine secretion by DCs (24). IL-10–
treated DCs promote the differentiation of naive T cells
into regulatory T cells, which in turn secrete IL-10. Our
data indicate that IL-10 increases TSP secretion by acti-
vated DCs. Kinetics of IL-10 and TSP release are very sim-
ilar during DC maturation. However, TSP inhibits IL-10
production. Thus, fully mDCs continue secreting TSP
whereas they stop producing IL-10 upon secondary stimu-
lation. Interestingly, interruption of TSP–CD47 by anti-
TSP mAb added at restimulation allows recovery of DC
cytokine production (including IL-10), suggesting the ex-
istence of alternate pathways to highly regulate cytokine re-
lease when DCs encounter T cells.
Furthermore, our findings show that DC-derived TSP
negatively regulates pro- and antiinflammatory cytokine
secretion during early activation through interactions with
CD47 and CD36. These results support our previous pa-
per that exogenous TSP and a peptide derived from the C
domain of TSP, which selectively binds to CD47, down-
regulate DC cytokine release, with the exception of TGF- 
(7). They are also consistent with a recent report indicat-
ing that anti-CD36 mAb delivers a negative signal to DCs,
resulting in decreased IL-12 production and phenotypic
maturation (6)
Most interestingly, we observed that physiologic con-
centrations of PGE2, and to a lesser extent TGF- , en-
hance TSP secretion by steady-state iDCs in the absence
of inflammatory signals. Both PGE2 and TGF-  are re-
portedly produced by macrophages after engulfment of
apoptotic cells and the latter secrete TGF-  (25, 26).
Thus, iDC-derived TSP may facilitate the phagocytosis
of apoptotic cells by at least two mechanisms. First,
TSP promotes CD47-mediated caspase-independent cell
death, characterized by increased phosphatidylserine ex-
posure on target cells (27). Second, it establishes a molec-
ular bridge between  v 3/CD36 on phagocytes and an
Figure 4. Endogenous TSP
negatively regulates cytokine
release and mediates DC ex-
haustion. (A) Monocyte-derived
iDCs were activated with SAC
for 48 h in the presence of neutral-
izing anti-TSP mAbs or respec-
tive control mAbs (10  g/ml).
Anti-TSP mAb III selectively
interferes with TSP–CD47 inter-
actions  and anti-TSP mAb I
with TSP–CD36 interactions.
Data are from one representative
experiment out of six. (B)
Monocyte-derived iDCs were
cultured for 48 h with SAC,
washed, and restimulated for 24 h
with L-CD40L transfectants
and IFN-  (to mimic T cell interactions) in the presence or absence of the two different neutralizing anti-TSP mAbs. Data are from one represen-
tative experiment out of four. IL-12, TNF- , and IL-10 production were determined by ELISA.T
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unidentified receptor, possibly CD47, on dying cells (17).
In that context, we postulate that iDC-derived TSP is
likely to be involved in phagocytosis of damaged tissues
by steady-state DCs that continuously tolerize lymph
node T cells. Furthermore, TSP inhibits early T cell acti-
vation and promotes naive T cell anergy (28, 29), and ac-
tive TGF-  displays potent immunoregulatory functions,
including prevention of DC maturation and activation of
regulatory T cells (15, 30). Altogether, it is possible that
PGE2 and TGF-  further amplify a TSP/TGF- /TSP-
positive immunoregulatory loop established to ensure tol-
erance in the steady state. Consistent with numerous anal-
yses, we observed that exogenous PGE2 strongly inhibits
cytokine release by activated DCs (3). Under these in-
flammatory conditions, PGE2, like TGF-  and IL-10,
markedly increases TSP.
Herein, we provide evidence that DC-derived TSP me-
diates DC exhaustion. After prolonged stimulation, DCs
secrete TSP and TGF-  and promote the generation of
nonpolarized T cells, a subset of central memory T cells (2).
We propose that TSP exerts its antiinflammatory activity
both in the steady state, contributing to the tolerogenic
function of DCs, and at the end of the inflammatory re-
sponse, allowing the rapid and active resolution of inflam-
mation. The in vivo biological relevance of the present in
vitro findings is supported strongly by the inflammatory
phenotype of TSP null mice.
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